Based on MitoTransfer
Who We Are
PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.
PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.
Seoul National University Hospital Research Collaboration
Pre-series A Funding
KRW 1,5 B
Series A Funding
KRW 6 B
KRW 4,5 B
Mitochondria GMP Facility
KBS 특별기획 코로나19 이후, 대한민국 길을 묻다
(주)파이안바이오테크놀로지 부분은 동영상 41-44분 참조 Source: https://vod.kbs.co.kr/index.html?source=episode&sname=vod&stype=vod&program_code=T2020-0336&program_id=PS-2021077030-01-000&broadcast_comp...Read more >>
2021년 과학정보통신의 날 국가연구개발성과 평가부문에서 '과학기술 포장' 수상
(주)파이안바이오테크놀로지 김천형 수석부사장 과학기술포장 수상 Source: https://news.v.daum.net/v/20210421114012208?f=mRead more >>